 Gilles Montalescot |  Freek Verheugt |
Angioplasty: Four-Continent RIVIERA Study Identifies “Real World” Modifiable Factors Which Affect Outcome
REFERENCE: Abstract 3413, “Hot Line II” Session, Abstract 649
Gilles Montalescot, Pitié-Salpêtriere Hospital, Paris
Angioplasty outcomes can be improved by modifying factors identified by the 8000-patient, 23-country, prospective, observational “RIVIERA” study presented at a “Hot Line” session of the cardiology congress in Barcelona. Gilles Montalescot discussed the rôle of pre-treatment with clopidogrel, the use of statins, radial rather than femoral access, and the choice of anticoagulation. Peter Goodwin asked him about his findings.
Coagulation Choices in Elective and Primary PCI
REFERENCE: “Hot Line II” Session
Freek Verheugt, Nijmegen University, Netherlands
Amid controversy in Barcelona about the choice of anticoagulation for patients receiving angioplasty Freek Verheugt commented on the relative merits of low-molecular weight heparin and the factor 10a inhibitor fondaparinux. He gave Peter Goodwin his reactions to recommendations emerging from the RIVIERA study of angioplasty outcome determinants.
